DE2220504A1 - Verfahren zur herstellung von arzneipraeparaten mit beschleunigter loeslichkeit - Google Patents
Verfahren zur herstellung von arzneipraeparaten mit beschleunigter loeslichkeitInfo
- Publication number
- DE2220504A1 DE2220504A1 DE2220504A DE2220504A DE2220504A1 DE 2220504 A1 DE2220504 A1 DE 2220504A1 DE 2220504 A DE2220504 A DE 2220504A DE 2220504 A DE2220504 A DE 2220504A DE 2220504 A1 DE2220504 A1 DE 2220504A1
- Authority
- DE
- Germany
- Prior art keywords
- drug
- solubility
- accelerated
- acid
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 6
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 150000002500 ions Chemical class 0.000 claims description 10
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 150000001450 anions Chemical class 0.000 claims description 8
- 229940126601 medicinal product Drugs 0.000 claims description 8
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 6
- 229960002803 methaqualone Drugs 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 4
- 239000004099 Chlortetracycline Substances 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004475 chlortetracycline Drugs 0.000 claims description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 2
- 235000019365 chlortetracycline Nutrition 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- 229960004909 aminosalicylic acid Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229910052573 porcelain Inorganic materials 0.000 description 2
- -1 propoxyphene ion Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLMALTXPSGQGBX-UHFFFAOYSA-N 1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate Chemical compound C=1C=CC=CC=1C(OC(=O)CC)(C(C)CN(C)C)CC1=CC=CC=C1 XLMALTXPSGQGBX-UHFFFAOYSA-N 0.000 description 1
- UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical compound CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229940065347 propoxyphene hydrochloride Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU63060 | 1971-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2220504A1 true DE2220504A1 (de) | 1973-02-15 |
Family
ID=19726690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2220504A Pending DE2220504A1 (de) | 1971-04-26 | 1972-04-26 | Verfahren zur herstellung von arzneipraeparaten mit beschleunigter loeslichkeit |
Country Status (6)
| Country | Link |
|---|---|
| CH (1) | CH540695A (https=) |
| DE (1) | DE2220504A1 (https=) |
| FR (1) | FR2134503B1 (https=) |
| GB (1) | GB1358001A (https=) |
| LU (1) | LU63060A1 (https=) |
| NL (1) | NL7205573A (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9103110D0 (sv) | 1991-10-24 | 1991-10-24 | Kabi Pharmacia Ab | New drug formulation |
| EP1140037A1 (en) * | 1999-01-07 | 2001-10-10 | ELAN CORPORATION, Plc | Multiparticulate oral dosage forms |
| CA2645855C (en) | 2006-03-16 | 2015-02-03 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR7017E (https=) * | ||||
| BE560809A (https=) * |
-
1971
- 1971-04-26 LU LU63060D patent/LU63060A1/xx unknown
-
1972
- 1972-04-21 CH CH598872A patent/CH540695A/fr not_active IP Right Cessation
- 1972-04-25 FR FR7214686A patent/FR2134503B1/fr not_active Expired
- 1972-04-25 NL NL7205573A patent/NL7205573A/xx unknown
- 1972-04-26 DE DE2220504A patent/DE2220504A1/de active Pending
- 1972-04-26 GB GB1928372A patent/GB1358001A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| LU63060A1 (https=) | 1971-08-26 |
| FR2134503B1 (https=) | 1976-07-02 |
| CH540695A (fr) | 1973-08-31 |
| NL7205573A (https=) | 1972-10-30 |
| FR2134503A1 (https=) | 1972-12-08 |
| GB1358001A (en) | 1974-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2813480C2 (de) | Arzneimittel-Depotpräparat vom Mehrfacheinheitsdosen-Typ | |
| DE69205971T2 (de) | Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten. | |
| DE2414868C3 (de) | Teilchenförmige Arzneimittel | |
| DE68909772T2 (de) | Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe. | |
| DE3320583A1 (de) | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung | |
| CH670566A5 (https=) | ||
| DD218373A5 (de) | Verfahren zur herstellung eines resinates einer substituierten carbonsaeure | |
| AT6542U1 (de) | Tamsulosinpellets und verfahren zum herstellen derselben | |
| DD263918A5 (de) | Verfahren zur herstellung von arzneimittelkombinationen | |
| EP0250648B1 (de) | Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen | |
| DE1492107A1 (de) | Verfahren zur Herstellung einer Tablette | |
| CH640738A5 (de) | Arzneimitteltablette zur peroralen applikation und verfahren zu deren herstellung. | |
| DE2611041A1 (de) | Retard-formulierung | |
| DE69128760T2 (de) | Antidiarrhoeika | |
| DE69225979T2 (de) | Orale zubereitung zur freisetzung im unteren verdauungstract | |
| DE3834794C2 (https=) | ||
| DE69008107T2 (de) | Zubereitung mit verzögerter Freigabe eines Hydrochlorids eines basischen Arzneistoffs. | |
| EP0150792B1 (de) | Arzneimittel und die Verwendung schwerlöslicher Calcium- und/oder Magnesiumverbindungen zur Herstellung eines Arzneimittels | |
| DE2220504A1 (de) | Verfahren zur herstellung von arzneipraeparaten mit beschleunigter loeslichkeit | |
| DD144719A5 (de) | Verfahren zur gewinnung einer natuerlichen polarfraktion mit antipsoriatischer wirksamkeit | |
| DE69433012T2 (de) | Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac | |
| DE1767831B1 (de) | Peroral zu verabreichendes Antidiarrhoikum | |
| EP0721785A2 (de) | Entbittertes Ranitidin-Präparat | |
| DE3839825A1 (de) | Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze | |
| DE2342460A1 (de) | Eisen- oder aluminiumglycyrrhizinat enthaltendes produkt, verfahren zu seiner herstellung und dieses produkt enthaltendes arzneimittel |